N	B:C0376322
-	I:C0376322
linked	I:C0376322
glycosylation	I:C0376322
of	O
SV2	O
is	O
required	O
for	O
binding	O
and	O
uptake	O
of	O
botulinum	O
neurotoxin	I:C0006050
A.	I:C0006050
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
(	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
)	O
,	O
a	O
licensed	O
drug	O
widely	O
used	O
for	O
medical	O
and	O
cosmetic	O
applications	O
,	O
exerts	O
its	O
action	O
by	O
invading	O
motoneurons	O
.	O

N	O
-	I:C0376322
linked	I:C0376322
glycosylation	I:C0376322
of	O
SV2	B:C3711414
is	O
required	O
for	O
binding	O
and	O
uptake	O
of	O
botulinum	O
neurotoxin	I:C0006050
A.	I:C0006050
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
(	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
)	O
,	O
a	O
licensed	O
drug	O
widely	O
used	O
for	O
medical	O
and	O
cosmetic	O
applications	O
,	O
exerts	O
its	O
action	O
by	O
invading	O
motoneurons	O
.	O

N	O
-	I:C0376322
linked	I:C0376322
glycosylation	I:C0376322
of	O
SV2	O
is	O
required	O
for	O
binding	B:C0033618
and	O
uptake	O
of	O
botulinum	O
neurotoxin	I:C0006050
A.	I:C0006050
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
(	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
)	O
,	O
a	O
licensed	O
drug	O
widely	O
used	O
for	O
medical	O
and	O
cosmetic	O
applications	O
,	O
exerts	O
its	O
action	O
by	O
invading	O
motoneurons	O
.	O

N	O
-	I:C0376322
linked	I:C0376322
glycosylation	I:C0376322
of	O
SV2	O
is	O
required	O
for	O
binding	O
and	O
uptake	B:C0243144
of	O
botulinum	O
neurotoxin	I:C0006050
A.	I:C0006050
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
(	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
)	O
,	O
a	O
licensed	O
drug	O
widely	O
used	O
for	O
medical	O
and	O
cosmetic	O
applications	O
,	O
exerts	O
its	O
action	O
by	O
invading	O
motoneurons	O
.	O

N	O
-	I:C0376322
linked	I:C0376322
glycosylation	I:C0376322
of	O
SV2	O
is	O
required	O
for	O
binding	O
and	O
uptake	O
of	O
botulinum	B:C0006050
neurotoxin	I:C0006050
A.	I:C0006050
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
(	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
)	O
,	O
a	O
licensed	O
drug	O
widely	O
used	O
for	O
medical	O
and	O
cosmetic	O
applications	O
,	O
exerts	O
its	O
action	O
by	O
invading	O
motoneurons	O
.	O

N	O
-	I:C0376322
linked	I:C0376322
glycosylation	I:C0376322
of	O
SV2	O
is	O
required	O
for	O
binding	O
and	O
uptake	O
of	O
botulinum	O
neurotoxin	I:C0006050
A.	I:C0006050
Botulinum	B:C0006050
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
(	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
)	O
,	O
a	O
licensed	O
drug	O
widely	O
used	O
for	O
medical	O
and	O
cosmetic	O
applications	O
,	O
exerts	O
its	O
action	O
by	O
invading	O
motoneurons	O
.	O

N	O
-	I:C0376322
linked	I:C0376322
glycosylation	I:C0376322
of	O
SV2	O
is	O
required	O
for	O
binding	O
and	O
uptake	O
of	O
botulinum	O
neurotoxin	I:C0006050
A.	I:C0006050
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
(	O
Botulinum	B:C0006050
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
)	O
,	O
a	O
licensed	O
drug	O
widely	O
used	O
for	O
medical	O
and	O
cosmetic	O
applications	O
,	O
exerts	O
its	O
action	O
by	O
invading	O
motoneurons	O
.	O

N	O
-	I:C0376322
linked	I:C0376322
glycosylation	I:C0376322
of	O
SV2	O
is	O
required	O
for	O
binding	O
and	O
uptake	O
of	O
botulinum	O
neurotoxin	I:C0006050
A.	I:C0006050
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
(	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
)	O
,	O
a	O
licensed	B:C0023636
drug	O
widely	O
used	O
for	O
medical	O
and	O
cosmetic	O
applications	O
,	O
exerts	O
its	O
action	O
by	O
invading	O
motoneurons	O
.	O

N	O
-	I:C0376322
linked	I:C0376322
glycosylation	I:C0376322
of	O
SV2	O
is	O
required	O
for	O
binding	O
and	O
uptake	O
of	O
botulinum	O
neurotoxin	I:C0006050
A.	I:C0006050
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
(	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
)	O
,	O
a	O
licensed	O
drug	B:C1254351
widely	O
used	O
for	O
medical	O
and	O
cosmetic	O
applications	O
,	O
exerts	O
its	O
action	O
by	O
invading	O
motoneurons	O
.	O

N	O
-	I:C0376322
linked	I:C0376322
glycosylation	I:C0376322
of	O
SV2	O
is	O
required	O
for	O
binding	O
and	O
uptake	O
of	O
botulinum	O
neurotoxin	I:C0006050
A.	I:C0006050
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
(	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
)	O
,	O
a	O
licensed	O
drug	O
widely	O
used	O
for	O
medical	B:C0013227
and	O
cosmetic	O
applications	O
,	O
exerts	O
its	O
action	O
by	O
invading	O
motoneurons	O
.	O

N	O
-	I:C0376322
linked	I:C0376322
glycosylation	I:C0376322
of	O
SV2	O
is	O
required	O
for	O
binding	O
and	O
uptake	O
of	O
botulinum	O
neurotoxin	I:C0006050
A.	I:C0006050
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
(	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
)	O
,	O
a	O
licensed	O
drug	O
widely	O
used	O
for	O
medical	O
and	O
cosmetic	O
applications	O
,	O
exerts	O
its	O
action	O
by	O
invading	O
motoneurons	B:C0026609
.	O

Here	O
we	O
report	O
a	O
2.0	O
-	O
Å-	O
resolution	O
crystal	B:C0444626
structure	I:C0444626
of	O
the	O
BoNT	O
/	I:C0006050
A1	I:C0006050
receptor	I:C0006050
-	O
binding	O
domain	I:C1514535
in	O
complex	O
with	O
its	O
neuronal	O
receptor	I:C2325760
,	O
glycosylated	O
human	O
SV2C	I:C3711414
.	O

Here	O
we	O
report	O
a	O
2.0	O
-	O
Å-	O
resolution	O
crystal	O
structure	I:C0444626
of	O
the	O
BoNT	B:C0006050
/	I:C0006050
A1	I:C0006050
receptor	I:C0006050
-	O
binding	O
domain	I:C1514535
in	O
complex	O
with	O
its	O
neuronal	O
receptor	I:C2325760
,	O
glycosylated	O
human	O
SV2C	I:C3711414
.	O

Here	O
we	O
report	O
a	O
2.0	O
-	O
Å-	O
resolution	O
crystal	O
structure	I:C0444626
of	O
the	O
BoNT	O
/	I:C0006050
A1	I:C0006050
receptor	I:C0006050
-	O
binding	B:C1514535
domain	I:C1514535
in	O
complex	O
with	O
its	O
neuronal	O
receptor	I:C2325760
,	O
glycosylated	O
human	O
SV2C	I:C3711414
.	O

Here	O
we	O
report	O
a	O
2.0	O
-	O
Å-	O
resolution	O
crystal	O
structure	I:C0444626
of	O
the	O
BoNT	O
/	I:C0006050
A1	I:C0006050
receptor	I:C0006050
-	O
binding	O
domain	I:C1514535
in	O
complex	B:C1704241
with	O
its	O
neuronal	O
receptor	I:C2325760
,	O
glycosylated	O
human	O
SV2C	I:C3711414
.	O

Here	O
we	O
report	O
a	O
2.0	O
-	O
Å-	O
resolution	O
crystal	O
structure	I:C0444626
of	O
the	O
BoNT	O
/	I:C0006050
A1	I:C0006050
receptor	I:C0006050
-	O
binding	O
domain	I:C1514535
in	O
complex	O
with	O
its	O
neuronal	B:C2325760
receptor	I:C2325760
,	O
glycosylated	O
human	O
SV2C	I:C3711414
.	O

Here	O
we	O
report	O
a	O
2.0	O
-	O
Å-	O
resolution	O
crystal	O
structure	I:C0444626
of	O
the	O
BoNT	O
/	I:C0006050
A1	I:C0006050
receptor	I:C0006050
-	O
binding	O
domain	I:C1514535
in	O
complex	O
with	O
its	O
neuronal	O
receptor	I:C2325760
,	O
glycosylated	B:C0376322
human	O
SV2C	I:C3711414
.	O

Here	O
we	O
report	O
a	O
2.0	O
-	O
Å-	O
resolution	O
crystal	O
structure	I:C0444626
of	O
the	O
BoNT	O
/	I:C0006050
A1	I:C0006050
receptor	I:C0006050
-	O
binding	O
domain	I:C1514535
in	O
complex	O
with	O
its	O
neuronal	O
receptor	I:C2325760
,	O
glycosylated	O
human	B:C3711414
SV2C	I:C3711414
.	O

We	O
found	O
that	O
the	O
neuronal	O
tropism	O
of	O
Botulinum	B:C0006050
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
requires	O
recognition	O
of	O
both	O
the	O
peptide	O
moiety	I:C0030956
and	O
an	O
N	O
-	I:C0032594
linked	I:C0032594
glycan	I:C0032594
on	O
SV2	O
.	O

We	O
found	O
that	O
the	O
neuronal	O
tropism	O
of	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
requires	O
recognition	O
of	O
both	O
the	O
peptide	B:C0030956
moiety	I:C0030956
and	O
an	O
N	O
-	I:C0032594
linked	I:C0032594
glycan	I:C0032594
on	O
SV2	O
.	O

We	O
found	O
that	O
the	O
neuronal	O
tropism	O
of	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
requires	O
recognition	O
of	O
both	O
the	O
peptide	O
moiety	I:C0030956
and	O
an	O
N	B:C0032594
-	I:C0032594
linked	I:C0032594
glycan	I:C0032594
on	O
SV2	O
.	O

We	O
found	O
that	O
the	O
neuronal	O
tropism	O
of	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
requires	O
recognition	O
of	O
both	O
the	O
peptide	O
moiety	I:C0030956
and	O
an	O
N	O
-	I:C0032594
linked	I:C0032594
glycan	I:C0032594
on	O
SV2	B:C3711414
.	O

This	O
N	B:C0032594
-	I:C0032594
glycan	I:C0032594
-	O
which	O
is	O
conserved	O
in	O
all	O
SV2	O
isoforms	O
across	O
vertebrates	O
-	O
is	O
essential	O
for	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
binding	O
to	O
neurons	O
and	O
for	O
its	O
potent	O
neurotoxicity	O
.	O

This	O
N	O
-	I:C0032594
glycan	I:C0032594
-	O
which	O
is	O
conserved	O
in	O
all	O
SV2	B:C3711414
isoforms	O
across	O
vertebrates	O
-	O
is	O
essential	O
for	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
binding	O
to	O
neurons	O
and	O
for	O
its	O
potent	O
neurotoxicity	O
.	O

This	O
N	O
-	I:C0032594
glycan	I:C0032594
-	O
which	O
is	O
conserved	O
in	O
all	O
SV2	O
isoforms	B:C0597298
across	O
vertebrates	O
-	O
is	O
essential	O
for	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
binding	O
to	O
neurons	O
and	O
for	O
its	O
potent	O
neurotoxicity	O
.	O

This	O
N	O
-	I:C0032594
glycan	I:C0032594
-	O
which	O
is	O
conserved	O
in	O
all	O
SV2	O
isoforms	O
across	O
vertebrates	B:C0042567
-	O
is	O
essential	O
for	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
binding	O
to	O
neurons	O
and	O
for	O
its	O
potent	O
neurotoxicity	O
.	O

This	O
N	O
-	I:C0032594
glycan	I:C0032594
-	O
which	O
is	O
conserved	O
in	O
all	O
SV2	O
isoforms	O
across	O
vertebrates	O
-	O
is	O
essential	O
for	O
Botulinum	B:C0006050
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
binding	O
to	O
neurons	O
and	O
for	O
its	O
potent	O
neurotoxicity	O
.	O

This	O
N	O
-	I:C0032594
glycan	I:C0032594
-	O
which	O
is	O
conserved	O
in	O
all	O
SV2	O
isoforms	O
across	O
vertebrates	O
-	O
is	O
essential	O
for	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
binding	B:C0033618
to	O
neurons	O
and	O
for	O
its	O
potent	O
neurotoxicity	O
.	O

This	O
N	O
-	I:C0032594
glycan	I:C0032594
-	O
which	O
is	O
conserved	O
in	O
all	O
SV2	O
isoforms	O
across	O
vertebrates	O
-	O
is	O
essential	O
for	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
binding	O
to	O
neurons	B:C0027882
and	O
for	O
its	O
potent	O
neurotoxicity	O
.	O

This	O
N	O
-	I:C0032594
glycan	I:C0032594
-	O
which	O
is	O
conserved	O
in	O
all	O
SV2	O
isoforms	O
across	O
vertebrates	O
-	O
is	O
essential	O
for	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
binding	O
to	O
neurons	O
and	O
for	O
its	O
potent	O
neurotoxicity	B:C0235032
.	O

The	O
glycan	B:C0032594
-	O
binding	O
interface	O
on	O
SV2	O
is	O
targeted	O
by	O
a	O
human	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
-	O
neutralizing	O
antibody	I:C0475463
currently	O
licensed	O
as	O
an	O
antibotulism	O
drug	I:C1254351
.	O

The	O
glycan	O
-	O
binding	B:C0033618
interface	O
on	O
SV2	O
is	O
targeted	O
by	O
a	O
human	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
-	O
neutralizing	O
antibody	I:C0475463
currently	O
licensed	O
as	O
an	O
antibotulism	O
drug	I:C1254351
.	O

The	O
glycan	O
-	O
binding	O
interface	O
on	O
SV2	B:C3711414
is	O
targeted	O
by	O
a	O
human	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
-	O
neutralizing	O
antibody	I:C0475463
currently	O
licensed	O
as	O
an	O
antibotulism	O
drug	I:C1254351
.	O

The	O
glycan	O
-	O
binding	O
interface	O
on	O
SV2	O
is	O
targeted	O
by	O
a	O
human	B:C0086418
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
-	O
neutralizing	O
antibody	I:C0475463
currently	O
licensed	O
as	O
an	O
antibotulism	O
drug	I:C1254351
.	O

The	O
glycan	O
-	O
binding	O
interface	O
on	O
SV2	O
is	O
targeted	O
by	O
a	O
human	O
Botulinum	B:C0006050
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
-	O
neutralizing	O
antibody	I:C0475463
currently	O
licensed	O
as	O
an	O
antibotulism	O
drug	I:C1254351
.	O

The	O
glycan	O
-	O
binding	O
interface	O
on	O
SV2	O
is	O
targeted	O
by	O
a	O
human	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
-	O
neutralizing	B:C0475463
antibody	I:C0475463
currently	O
licensed	O
as	O
an	O
antibotulism	O
drug	I:C1254351
.	O

The	O
glycan	O
-	O
binding	O
interface	O
on	O
SV2	O
is	O
targeted	O
by	O
a	O
human	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
-	O
neutralizing	O
antibody	I:C0475463
currently	O
licensed	B:C0023636
as	O
an	O
antibotulism	O
drug	I:C1254351
.	O

The	O
glycan	O
-	O
binding	O
interface	O
on	O
SV2	O
is	O
targeted	O
by	O
a	O
human	O
Botulinum	O
neurotoxin	I:C0006050
serotype	I:C0006050
A1	I:C0006050
-	O
neutralizing	O
antibody	I:C0475463
currently	O
licensed	O
as	O
an	O
antibotulism	B:C1254351
drug	I:C1254351
.	O

Our	O
studies	O
reveal	O
a	O
new	O
paradigm	O
of	O
host	B:C1752856
-	I:C1752856
pathogen	I:C1752856
interactions	I:C1752856
,	O
in	O
which	O
pathogens	O
exploit	O
conserved	O
host	O
post	O
-	I:C0033666
translational	I:C0033666
modifications	I:C0033666
,	O
thereby	O
achieving	O
highly	O
specific	O
receptor	O
binding	I:C0597358
while	O
also	O
tolerating	O
genetic	O
changes	I:C1705285
across	O
multiple	O
isoforms	O
of	O
receptors	O
.	O

Our	O
studies	O
reveal	O
a	O
new	O
paradigm	O
of	O
host	O
-	I:C1752856
pathogen	I:C1752856
interactions	I:C1752856
,	O
in	O
which	O
pathogens	O
exploit	O
conserved	O
host	O
post	B:C0033666
-	I:C0033666
translational	I:C0033666
modifications	I:C0033666
,	O
thereby	O
achieving	O
highly	O
specific	O
receptor	O
binding	I:C0597358
while	O
also	O
tolerating	O
genetic	O
changes	I:C1705285
across	O
multiple	O
isoforms	O
of	O
receptors	O
.	O

Our	O
studies	O
reveal	O
a	O
new	O
paradigm	O
of	O
host	O
-	I:C1752856
pathogen	I:C1752856
interactions	I:C1752856
,	O
in	O
which	O
pathogens	O
exploit	O
conserved	O
host	O
post	O
-	I:C0033666
translational	I:C0033666
modifications	I:C0033666
,	O
thereby	O
achieving	O
highly	O
specific	O
receptor	B:C0597358
binding	I:C0597358
while	O
also	O
tolerating	O
genetic	O
changes	I:C1705285
across	O
multiple	O
isoforms	O
of	O
receptors	O
.	O

Our	O
studies	O
reveal	O
a	O
new	O
paradigm	O
of	O
host	O
-	I:C1752856
pathogen	I:C1752856
interactions	I:C1752856
,	O
in	O
which	O
pathogens	O
exploit	O
conserved	O
host	O
post	O
-	I:C0033666
translational	I:C0033666
modifications	I:C0033666
,	O
thereby	O
achieving	O
highly	O
specific	O
receptor	O
binding	I:C0597358
while	O
also	O
tolerating	O
genetic	B:C1705285
changes	I:C1705285
across	O
multiple	O
isoforms	O
of	O
receptors	O
.	O

Our	O
studies	O
reveal	O
a	O
new	O
paradigm	O
of	O
host	O
-	I:C1752856
pathogen	I:C1752856
interactions	I:C1752856
,	O
in	O
which	O
pathogens	O
exploit	O
conserved	O
host	O
post	O
-	I:C0033666
translational	I:C0033666
modifications	I:C0033666
,	O
thereby	O
achieving	O
highly	O
specific	O
receptor	O
binding	I:C0597358
while	O
also	O
tolerating	O
genetic	O
changes	I:C1705285
across	O
multiple	O
isoforms	B:C0597298
of	O
receptors	O
.	O

Our	O
studies	O
reveal	O
a	O
new	O
paradigm	O
of	O
host	O
-	I:C1752856
pathogen	I:C1752856
interactions	I:C1752856
,	O
in	O
which	O
pathogens	O
exploit	O
conserved	O
host	O
post	O
-	I:C0033666
translational	I:C0033666
modifications	I:C0033666
,	O
thereby	O
achieving	O
highly	O
specific	O
receptor	O
binding	I:C0597358
while	O
also	O
tolerating	O
genetic	O
changes	I:C1705285
across	O
multiple	O
isoforms	O
of	O
receptors	B:C0597357
.	O

